Results 161 to 170 of about 5,770 (216)

L‑type amino acid transporter 1 in enhancing boron neutron capture therapy: Mechanisms, challenges and future directions (Review). [PDF]

Int J Mol Med
Zheng X, Pan J, Lin D, Shao W.
europepmc   +1 more source

A LAT1-selective PET tracer, 5-[¹⁸F]F-αMe-3BPA, as a companion to its structurally matched ¹⁰B analog in boron neutron capture therapy. [PDF]

Eur J Nucl Med Mol Imaging
Kondo N, Hirano F, Kanai Y, Suzuki K, Miyazaki A, Temma T.   +5 more
europepmc   +1 more source

Predictive factors of oral mucositis in patients with locally recurrent inoperable head and neck cancer treated with boron neutron capture therapy. [PDF]

Acta Oncol
Mälkiä T, Koivunoro H, Seppälä T, Kankaanranta L, Porra L, Anttonen A, Tenhunen M, Joensuu H.   +7 more
europepmc   +1 more source

Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges. [PDF]

Biomater Res
Ahmad F.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Boron and gadolinium neutron capture therapy

Russian Chemical Bulletin, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Masao Takagaki, Narayan S Hosmane
exaly   +2 more sources

Dose prescription in boron neutron capture therapy

International Journal of Radiation Oncology*Biology*Physics, 1994
The purpose of this paper is to address some aspects of the many considerations that need to go into a dose prescription in boron neutron capture therapy (BNCT) for brain tumors; and to describe some methods to incorporate knowledge from animal studies and other experiments into the process of dose prescription.Previously, an algorithm to estimate the ...
N, Gupta, R A, Gahbauer, T E, Blue, A, Wambersie   +3 more
openaire   +3 more sources

Boron Neutron Capture Therapy for Cancer

Scientific American, 1990
Boron neutron capture therapy (BNCT) bring together two components that when kept separate have only minor effects on normal cells. The first component is a stable isotope of boron (boron 10) that can be concentrated in tumor cells. The second is a beam of low-energy neutrons that produces short-range radiation when absorbed, or captured, by the boron.
R F, Barth, A H, Soloway, R G, Fairchild
openaire   +3 more sources

Boron neutron capture therapy for glioblastoma

Cancer Letters, 2008
Boron neutron capture therapy (BNCT) theoretically allows the preferential destruction of tumor cells while sparing the normal tissue, even if the cells have microscopically spread to the surrounding normal brain. The tumor cell-selective irradiation used in this method is dependent on the nuclear reaction between the stable isotope of boron ((10)B ...
Tetsuya, Yamamoto, Kei, Nakai, Akira, Matsumura   +2 more
openaire   +2 more sources

Microdosimetry for Boron Neutron Capture Therapy

Radiation Research, 1992
Preclinical studies for boron neutron capture therapy (BNCT) using epithermal neutrons are ongoing at several laboratories. The absorbed dose in tumor cells is a function of the thermal neutron flux at depth, the microscopic boron concentration, and the size of the cell.
C S, Wuu, H I, Amols, P, Kliauga, L E, Reinstein, S, Saraf   +4 more
openaire   +2 more sources

Utilizing neutron generators in boron neutron capture therapy

Applied Radiation and Isotopes, 2021
Neutron capture therapy (NCT) is a radiotherapeutic technique that is designed to utilize the neutron capture reaction and damage the tumor cells through the energy release from the reaction. Nuclear reactors are typically utilized in this therapy because of the high neutron fluence rate that can be achieved. There has been minimal work to evaluate the
Walid A, Metwally, Yumna, Adel, Entesar Z, Dalah, Husam, Al-Omari   +3 more
openaire   +2 more sources